Base de dados : LILACS
Pesquisa : E05.318.740.500.700 [Categoria DeCS]
Referências encontradas : 135 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 14 ir para página                         

  1 / 135 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-838097
Autor: Dedinská, Ivana; Laca, Ludovit; Miklusica, Juraj; Palkoci, Blazej; Skálová, Petra; Lauková, Slavomíra; Osinová, Denisa; Strmenová, Simona; Janík, Ján; Mokán, Marián.
Título: Complications of Liver Resection in Geriatric Patients
Fonte: Ann. hepatol;16(1):149-156, Jan.-Feb. 2017. graf.
Idioma: en.
Resumo: Abstract: Introduction and aims. Liver resection is the treatment of choice for many primary and secondary liver diseases. Most studies in the elderly have reported resection of primary and secondary liver tumors, especially hepatocellular carcinoma and colorectal metastatic cancer. However, over the last two decades, hepatectomy has become safe and is now performed in the older population, implying a paradigm shift in the approach to these patients. Material and methods. We retrospectively evaluated the risk factors for postoperative complications in patients over 65 years of age in comparison with those under 65 years of age after liver resection (n = 360). The set comprised 127 patients older than 65 years (35%) and 233 patients younger than 65 years (65%). Results. In patients younger than 65 years, there was a significantly higher incidence of benign liver tumors (P = 0.0073); in those older than 65 years, there was a significantly higher incidence of metastasis of colorectal carcinoma to the liver (0.0058). In patients older tan 65 years, there were significantly more postoperative cardiovascular complications (P = 0.0028). Applying multivariate analysis, we did not identify any independent risk factors for postoperative complications. The 12-month survival was not significantly different (younger versus older patients), and the 5-year survival was significantly worse in older patients (P = 0.0454). Conclusion. In the case of liver resection, age should not be a contraindication. An individualized approach to the patient and multidisciplinary postoperative care are the important issues.
Descritores: Complicações Pós-Operatórias/epidemiologia
Ablação por Cateter/efeitos adversos
Hepatectomia/efeitos adversos
Neoplasias Hepáticas/cirurgia
-Complicações Pós-Operatórias/diagnóstico
Complicações Pós-Operatórias/mortalidade
Fatores de Tempo
Distribuição de Qui-Quadrado
Modelos de Riscos Proporcionais
Incidência
Análise Multivariada
Estudos Retrospectivos
Fatores de Risco
Fatores Etários
Resultado do Tratamento
Ablação por Cateter/mortalidade
Eslováquia
Medição de Risco
Seleção de Pacientes
Estimativa de Kaplan-Meier
Hepatectomia/métodos
Hepatectomia/mortalidade
Neoplasias Hepáticas/mortalidade
Neoplasias Hepáticas/patologia
Limites: Humanos
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  2 / 135 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Saúde Pública
Texto completo
Id: biblio-890185
Autor: Melo, Márcio Cristiano de; Donalisio, Maria Rita; Cordeiro, Ricardo Carlos.
Título: Sobrevida de pacientes com AIDS e coinfecção pelo bacilo da tuberculose nas regiões Sul e Sudeste do Brasil / Survival of patients with AIDS and co-infection with the tuberculosis bacillus in the South and Southeast regions of Brazil
Fonte: Ciênc. Saúde Colet;22(11):3781-3792, Nov. 2017. tab, graf.
Idioma: pt.
Resumo: Resumo O presente estudo buscou analisar a sobrevida de pacientes com a coinfecção AIDS-Tuberculose por meio de um estudo de coorte retrospectivo de indivíduos com 13 anos ou mais e diagnóstico de AIDS notificados nos anos de 1998-99 e seguimento de 10 anos. Dos 2.091 casos de AIDS, 517 (24,7%) tinham diagnóstico positivo para tuberculose, sendo 379 (73,3%) masculinos. O risco entre os coinfectados foi 1,65 vezes os não coinfectados. As variáveis associadas à maior sobrevida foram: sexo feminino (HR = 0,63), escolaridade ≥ oito anos (HR = 0,52), critério diagnóstico CD4 (HR = 0,64); e à menor sobrevida: faixa etária ≥ 60 anos (HR = 2,33), não uso de ARV (HR = 8,62), não investigação para hepatite B (HR = 2,44) e doenças oportunistas (≥ duas) (HR = 1,97). A sobrevivência acumulada foi de 71% nos não coinfectados e 62% nos coinfectados na região Sul e de 74% e 58%, respectivamente, na região Sudeste, 60 meses após o diagnóstico de AIDS. A AIDS e a Tuberculose exigem acompanhamento e adesão ao tratamento e são marcadores da atenção à saúde e da sobrevivência dos pacientes no Brasil.

Abstract The study investigates the survival of patients with co-infection AIDS-TB through a retrospective study of a cohort of individuals aged 13 or more and the diagnosis of AIDS reported in the years 1998-99 and following 10 years. Of the 2,091 AIDS cases, 517 (24.7%) had positive diagnosis for tuberculosis, and 379 (73.3%) were male. The risk among co-infected patients was 1,65 times the not co-infected. Have been compared the exposed and non-exposed through the Kaplan-Meier and Cox method. The variables associated with longer survival were: female gender (HR = 0.63), educational level ≥ eight years (HR = 0.52), CD4 diagnostic criteria (HR = 0.64); and shorter survival: age ≥ 60 years (HR = 2.33), no use of HAART (HR = 8.62), no investigation to Hepatitis B (HR = 2.44) and opportunistic infections ≥ two (HR = 1.97). The average survival rate, related to TB infection was 69 months for the Southeast region and 73 months for the South. AIDS and tuberculosis require monitoring and treatment adherence and they are markers of the quality of care and survival of patients in Brazil.
Descritores: Tuberculose/mortalidade
Síndrome de Imunodeficiência Adquirida/mortalidade
Infecções Oportunistas Relacionadas com a AIDS/mortalidade
Adesão à Medicação
-Tuberculose/tratamento farmacológico
Tuberculose/epidemiologia
Brasil/epidemiologia
Modelos de Riscos Proporcionais
Fatores Sexuais
Taxa de Sobrevida
Estudos Retrospectivos
Fatores de Risco
Estudos de Coortes
Fatores Etários
Síndrome de Imunodeficiência Adquirida/tratamento farmacológico
Síndrome de Imunodeficiência Adquirida/epidemiologia
Infecções Oportunistas Relacionadas com a AIDS/epidemiologia
Terapia Antirretroviral de Alta Atividade
Estimativa de Kaplan-Meier
Coinfecção
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Adulto Jovem
Responsável: BR1.1 - BIREME


  3 / 135 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Saúde Pública
Texto completo
Id: biblio-890211
Autor: Ferraz, Rosemeire de Olanda; Moreira-Filho, Djalma de Carvalho.
Título: Análise de sobrevivência de mulheres com câncer de mama: modelos de riscos competitivos / Survival analysis of women with breast cancer: competing risk models
Fonte: Ciênc. Saúde Colet;22(11):3743-3754, Nov. 2017. tab, graf.
Idioma: pt.
Resumo: Resumo O objetivo deste estudo foi estimar os efeitos de fatores prognósticos na sobrevida do câncer de mama, como idade, estadiamento e extensão do tumor, utilizando modelos de riscos proporcionais de Cox e de riscos competitivos de Fine-Gray. É um estudo de coorte retrospectiva de base-populacional referente a 524 mulheres diagnosticadas com câncer de mama no período de 1993 a 1995, acompanhadas até 2011, residentes no município de Campinas, São Paulo, Brasil. O ponto de corte (cutoff) da variável idade foi definido utilizando-se modelos simples de Cox. Nos ajustes de modelos simples e múltiplo de Fine-Gray, a idade não foi significativa na presença de riscos competitivos e nem nos modelos de Cox, considerando-se, para ambas as modelagens, óbito por câncer de mama como desfecho de interesse. As curvas de sobrevidas estimadas por Kaplan-Meier evidenciaram diferenças expressivas para óbitos por câncer de mama e por riscos competitivos. As curvas de sobrevida por câncer de mama não apresentaram diferenças significativas quando comparados os grupos de idades, segundo teste de log rank. Os modelos de Cox e de Fine-Gray identificaram os mesmos fatores prognósticos que influenciavam na sobrevida do câncer de mama.

Abstract This study aimed to estimate the effects of prognostic factors on breast cancer survival, such as age, staging, and extension of the tumor, using proportional hazards and competing risks models proposed by Cox and Fine-Gray, respectively. This is a retrospective cohort study, based on a population of 524 women, who were diagnosed with breast cancer in the period from 1993 to 1995 and monitored until 2011, residents in the city of Campinas, São Paulo, Brazil. The cutoff points for the variable of age were defined with Cox simple models. In the settings of simple and multiple Fine-Gray models, age was not significant to the presence of competing risks, neither it was in Cox models. For both models, death by breast cancer was the event of interest. The survival functions, estimated by Kaplan-Meier, showed significant differences for deaths by breast cancer and by competing risks. Survival functions by breast cancer did not show significant differences when comparing the age groups, according to log-rank test. Cox and Fine-Gray models identified the same prognostic factors that influenced in breast cancer survival.
Descritores: Neoplasias da Mama/patologia
Modelos Estatísticos
-Prognóstico
Brasil/epidemiologia
Neoplasias da Mama/epidemiologia
Modelos de Riscos Proporcionais
Análise de Sobrevida
Estudos Retrospectivos
Fatores de Risco
Estudos de Coortes
Fatores Etários
Pessoa de Meia-Idade
Estadiamento de Neoplasias
Limites: Humanos
Feminino
Adulto
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  4 / 135 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887228
Autor: Karvellas, Constantine J; Cardoso, Filipe S; Senzolo, Marco; Wells, Malcolm; Alghanem, Mansour G; Handou, Fayaz; Kwapisz, Lukasz; Kneteman, Norman M; Marotta, Paul J; Al-Judaibi, Bandar.
Título: Clinical Impact of Portal Vein Thrombosis Prior to Liver Transplantation: A Retrospective Cohort Study
Fonte: Ann. hepatol;16(2):236-246, Mar.-Apr. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction. To identify the impact of portal vein thrombosis (PVT) and associated medical and surgical factors on outcomes post liver transplant (LT). Material and methods. Two analyses were performed. Analysis One: cohort study of 505 consecutive patients who underwent LT (Alberta) between 01/2002-12/2012. PVT was identified in 61 (14%) patients. Analysis Two: cohort study of 144 consecutive PVT patients from two sites (Alberta and London) during the same period. Cox multivariable survival analysis was used to identify independent associations with post-LT mortality. Results. In Analysis One (Alberta), PVT was not associated with post-LT mortality (log rank p = 0.99). On adjusted analysis, complete/occlusive PVT was associated with increased mortality (Hazard Ratio (HR) 8.4, p < 0.001). In Analysis Two (Alberta and London), complete/occlusive PVT was associated with increased mortality only on unadjusted analysis (HR 3.7, p = 0.02). On adjusted analysis, Hepatitis C (HR 2.1, p = 0.03) and post-LT portal vein re-occlusion (HR 3.2, p = 0.01) were independently associated with increased mortality. Conclusion: Well-selected LT patients who had PVT prior to LT had similar post-LT outcomes to non-PVT LT recipients. Subgroups of PVT patients who did worse post-LT (complete/occlusive thrombosis pre-LT, Hepatitis C or post-LT portal vein re-occlusion) warrant closer evaluation in listing and management post-LT.
Descritores: Veia Porta
Transplante de Fígado
Trombose Venosa/complicações
Doença Hepática Terminal/cirurgia
Cirrose Hepática/cirurgia
-Veia Porta/diagnóstico por imagem
Fatores de Tempo
Distribuição de Qui-Quadrado
Modelos de Riscos Proporcionais
Análise Multivariada
Estudos Retrospectivos
Transplante de Fígado/efeitos adversos
Transplante de Fígado/mortalidade
Resultado do Tratamento
Hepatite C/complicações
Trombose Venosa/cirurgia
Trombose Venosa/mortalidade
Trombose Venosa/diagnóstico por imagem
Estimativa de Kaplan-Meier
Doença Hepática Terminal/diagnóstico
Doença Hepática Terminal/mortalidade
Doença Hepática Terminal/virologia
Cirrose Hepática/diagnóstico
Cirrose Hepática/mortalidade
Cirrose Hepática/virologia
Responsável: BR1.1 - BIREME


  5 / 135 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Mattos, Angelo Alves de
Texto completo
Id: biblio-887231
Autor: Branco, Fernanda; Alencar, Regiane S. M; Volt, Fernanda; Sartori, Giovana; Dode, Andressa; Kikuchi, Luciana; Tani, Claudia M; Chagas, Aline L; Pfiffer, Tulio; Hoff, Paulo; Carrilho, Flair J; Mattos, Angelo Alves de.
Título: The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
Fonte: Ann. hepatol;16(2):263-268, Mar.-Apr. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Background and Aims. The presence of dermatologic reaction as an adverse event to sorafenib treatment in patients with unresectable hepatocellular carcinoma has been indicated as a prognostic factor for survival in a recent prospective analysis. To date, this is the only clinical predictor of treatment response, which can be evaluated earlier in the treatment and, therefore, contribute to a better and more individualized patient management. Material and methods. This retrospective study included 127 patients treated with sorafenib under real-life practice conditions in two hepatology reference centers in Brazil. Demographic data, disease/medical history and time of sorafenib administration as well as adverse events related to the medication were recorded in a database. Results. Cirrhosis was present in 94% of patients, 85.6% were Child-Pugh A, 80.3%BCLC-C, 81% had vascular invasion and/or extrahepatic spread and 95% had a performance status 0 to 1.The median duration of treatment was 10.1 months (range: 0.1-47 months).The most common adverse event within the first 60 days of treatment were diarrhea (62.2%) and dermatological reaction (42%).The median overall survival for the cohort was 20 months, and it was higher for patients who developed dermatological reactions within the first 60 days compared to those who did not present this adverse event. Conclusion. This retrospective analysis showed the use of sorafenib in patients selected according to BCLC staging, and it is the first external validation of early dermatologic adverse events as a predictor of overall survival in patients with advanced hepatocellular carcinoma.
Descritores: Compostos de Fenilureia/efeitos adversos
Niacinamida/análogos & derivados
Erupção por Droga/etiologia
Carcinoma Hepatocelular/tratamento farmacológico
Neoplasias Hepáticas/tratamento farmacológico
Antineoplásicos/efeitos adversos
-Fatores de Tempo
Modelos de Riscos Proporcionais
Estudos Retrospectivos
Fatores de Risco
Resultado do Tratamento
Niacinamida/efeitos adversos
Erupção por Droga/diagnóstico
Erupção por Droga/mortalidade
Carcinoma Hepatocelular/mortalidade
Carcinoma Hepatocelular/patologia
Estimativa de Kaplan-Meier
Sorafenibe
Neoplasias Hepáticas/mortalidade
Neoplasias Hepáticas/patologia
Estadiamento de Neoplasias
Limites: Humanos
Responsável: BR1.1 - BIREME


  6 / 135 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1152054
Autor: Gauna, Alan Gabriel.
Título: En mayores de 60 años el tabaquismo activo duplica la mortalidad cardiovascular y su cesación la reduce / In adults over 60 years, active smoking doubles the risk of cardiovascular mortality and quitting reduces it
Fonte: Evid. actual. práct. ambul;19(3):84-84, 2016. tab.
Idioma: es.
Descritores: Tabagismo/mortalidade
Doenças Cardiovasculares/mortalidade
-Doenças Cardiovasculares/prevenção & controle
Fumar/mortalidade
Modelos de Riscos Proporcionais
Conhecimentos, Atitudes e Prática em Saúde
Metanálise como Assunto
Incidência
Fatores de Risco
Fatores Etários
Abandono do Hábito de Fumar
Acidente Vascular Cerebral/mortalidade
Acidente Vascular Cerebral/prevenção & controle
Europa (Continente)
Prevenção do Hábito de Fumar
América do Norte
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Comentário
Responsável: AR2.1 - Biblioteca Central


  7 / 135 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887252
Autor: Palmer, William C; Lee, David; Burns, Justin; Croome, Kristopher; Rosser, Barry; Patel, Tushar; Keaveny, Andrew P; Pungpapong, Surakit; Satyanarayana, Raj; Yataco, Maria; Nakhleh, Raouf; Musto, Kaitlyn R; Canabal, Alexandra M; Turnage, Alex K; Hodge, David O; Nguyen, Justin H; Harnois, Denise M.
Título: Liver Transplantation for Hepatocellular Carcinoma: Impact of Wait Time at a Single Center
Fonte: Ann. hepatol;16(3):402-411, May.-Jun. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction and aim. Liver transplantation (LT) provides durable survival for hepatocellular carcinoma (HCC). However, there is continuing debate concerning the impact of wait time and acceptable tumor burden on outcomes after LT. We sought to review outcomes of LT for HCC at a single, large U.S. center, examining the influence of wait time on post-LT outcomes. Material and methods. We reviewed LT for HCC at Mayo Clinic in Florida from 1/1/2003 until 6/30/2014. Follow up was updated through 8/1/ 2015. Results. From 2003-2014,978 patients were referred for management of HCC. 376 patients were transplanted for presumed HCC within Milan criteria, and the results of these 376 cases were analyzed. The median diagnosis to LT time was 183 days (8 - 4,337), and median transplant list wait time was 62 days (0 -1815). There was no statistical difference in recurrence-free or overall survival for those with wait time of less than or greater than 180 days from diagnosis of HCC to LT. The most important predictor of long term survival after LT was HCC recurrence (HR: 18.61, p < 0.001). Recurrences of HCC as well as survival were predicted by factors related to tumor biology, including histopathological grade, vascular invasion, and pre-LT serum alpha-fetoprotein levels. Disease recurrence occurred in 13%. The overall 5-year patient survival was 65.8%, while the probability of 5-year recurrence-free survival was 62.2%. Conclusions. In this large, single-center experience with long-term data, factors of tumor biology, but not a longer wait time, were associated with recurrence-free and overall survival.
Descritores: Transplante de Fígado/efeitos adversos
Transplante de Fígado/mortalidade
Carcinoma Hepatocelular/cirurgia
Carcinoma Hepatocelular/diagnóstico
Carcinoma Hepatocelular/mortalidade
Recidiva Local de Neoplasia
-Fatores de Tempo
Modelos de Riscos Proporcionais
Fatores de Risco
Listas de Espera/mortalidade
Intervalo Livre de Doença
Estimativa de Kaplan-Meier
Análise de Intenção de Tratamento
Tempo para o Tratamento
Neoplasias Hepáticas/cirurgia
Neoplasias Hepáticas/diagnóstico
Neoplasias Hepáticas/mortalidade
Limites: Humanos
Responsável: BR1.1 - BIREME


  8 / 135 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887253
Autor: Qu, Li-Shuai; Liu, Jin-Xia; Zhu, Jing; Lu, Cui-Hua.
Título: Risk Factors for Prognosis of Hepatocellular Carcinoma After Curative Resection In Patients with Low Hepatitis B Viral Load
Fonte: Ann. hepatol;16(3):412-420, May.-Jun. 2017. tab, graf.
Idioma: en.
Projeto: National Nature Science Foundation of China; . China Ministry of Health; . Natural Science Foundation of Jiangsu Province; . Foundation of Jiangsu Province.
Resumo: ABSTRACT Background. A retrospective cohort study was conducted to investigate the effect of hepatitis B surface antigen (HBsAg) level on prognosis in low viral load (< 2000 lU/mL) patients with hepatitis B-related hepatocellular carcinoma (HCC) after curative resection. Material and methods. A total of 192 patients with low viral load who had received curative resection of pathologically confirmed HCC were analyzed to determine the factors affecting prognosis. The risk factors for survival, early and late recurrence (2 years as a cut-off) were studied. Results. The median follow-up time was 38.5 months. The overall survival rates at 1-, 3-, and 5-year after curative resection were 94.2%, 64.0%, and 45.2%, respectively. The cumulative recurrence rates at 1-, 3-, and 5-year after curative resection were 22.4%, 46.5%, and 67.0%, respectively. Patients with high serum HBsAg levels (> 250 lU/mL) had significantly lower survival rates than those with low HBsAg levels (HR: 1.517,95% Cl: 1.005-2.292, P = 0.047). Stratified analysis showed that patients with high HBsAg levels had a significantly higher late recurrence incidence than those with low HBsAg levels (HR: 2.155, 95% Cl: 1.094-4.248, P = 0.026), but did not have a significantly higher risk of early recurrence postoperatively (HR: 1.320,95% Cl: 0. 837-2.082, P = 0.233). Multivariate analysis revealed that HBsAg > 250 lU/mL was an independent risk factor associated with late recurrence (HR: 2.109, 95% Cl: 1.068-4.165, P = 0.032). Conclusions. HBsAg > 250 lU/mL at the time of tumor resection was an independent risk factor for late recurrence in low viral load HCC patients.
Descritores: Carcinoma Hepatocelular/cirurgia
Carcinoma Hepatocelular/diagnóstico
Carcinoma Hepatocelular/virologia
Hepatectomia/efeitos adversos
Antígenos de Superfície da Hepatite B/sangue
-Fatores de Tempo
Biomarcadores/sangue
Modelos de Riscos Proporcionais
Vírus da Hepatite B/imunologia
Análise Multivariada
Estudos Retrospectivos
Fatores de Risco
Resultado do Tratamento
Intervalo Livre de Doença
Progressão da Doença
Estimativa de Kaplan-Meier
Hepatite B/complicações
Hepatite B/diagnóstico
Hepatite B/virologia
Recidiva Local de Neoplasia
Limites: Humanos
Responsável: BR1.1 - BIREME


  9 / 135 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887254
Autor: Chaiteerakij, Roongruedee; Chattieng, Piyanat; Choi, Jonggi; Pinchareon, Nutcha; Thanapirom, Kessirin; Geratikornsupuk, Nopavut.
Título: Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis
Fonte: Ann. hepatol;16(3):421-429, May.-Jun. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Background. Evidence supporting benefit of hepatocellular carcinoma (HCC) surveillance in reducing mortality is not well-established. The effect of HCC surveillance in reducing mortality was assessed by an inverse probability of treatment weighting (IPTW)- based analysis controlled for inherent bias and confounders in observational studies. Material and methods. This retrospective cohort study was conducted on 446 patients diagnosed with HCC between 2007 and 2013 at a major referral center. Surveillance was defined as having at least 1 ultrasound test within a year before HCC diagnosis. Primary outcome was survival estimated using the Kaplan-Meier method with lead-time bias adjustment and compared using the log-rank test. Hazard ratio (HR) and 95% confidence interval (Cl) were computed using conventional Cox and weighted Cox proportional hazards analysis with IPTW adjustment. Results. Of the 446 patients, 103 (23.1%) were diagnosed with HCC through surveillance. The surveillance group had more patients with the Barcelona-Clinic Liver Cancer stage A (80.6% vs. 33.8%, P < 0.0001), more patients eligible for potentially curative treatment (73.8% vs. 44.9%, P < 0.0001), and longer median survival (49.6 vs. 15.9 months, P < 0.0001). By conventional multivariate Cox analysis, HR (95% Cl) of surveillance was 0.63 (0.45-0.87), P = 0.005. The estimated effect of surveillance remained similar in the IPTW-adjusted Cox analysis (HR: 0.57; 95% Cl: 0.43-0.76, P < 0.001). Conclusions. HCC surveillance by ultrasound is associated with a 37% reduction in mortality. Even though surveillance is recommended in all guidelines, but in practice, it is underutilized. Interventions are needed to increase surveillance rate for improving HCC outcome.
Descritores: Carcinoma Hepatocelular/mortalidade
Carcinoma Hepatocelular/terapia
Carcinoma Hepatocelular/diagnóstico por imagem
-Tailândia
Fatores de Tempo
Efeito de Coortes
Modelos de Riscos Proporcionais
Valor Preditivo dos Testes
Estudos Retrospectivos
Ultrassonografia/normas
Guias de Prática Clínica como Assunto
Medição de Risco
Estimativa de Kaplan-Meier
Detecção Precoce de Câncer/métodos
Neoplasias Hepáticas/mortalidade
Neoplasias Hepáticas/terapia
Neoplasias Hepáticas/diagnóstico por imagem
Estadiamento de Neoplasias
Limites: Humanos
Responsável: BR1.1 - BIREME


  10 / 135 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-952725
Autor: Souza, Marco Antônio Comper de; Zacchi, Sérgio Riguete; Viana, Katia Cirlene Gomes; Souza, Camila Brandão de; Zandonade, Eliana; Amorim, Maria Helena Costa.
Título: Survival analysis of penile cancer patients treatedat a tertiary oncology hospital / Análise de sobrevida de pacientes com câncer de pênis tratados em um hospital oncológico terciário
Fonte: Ciênc. Saúde Colet;23(8):2479-2486, Aug. 2018. tab, graf.
Idioma: en.
Resumo: Abstract This article aims to estimate the specific survival of patients with penile cancer treated at a state tertiary oncology hospital. The study included 100 cases incidents patients with penile cancer treated at a cancer center, from 2000 to 2011, follow-up to December 31, 2012. The hospital-based cancer registry and medical records were used as data sources. We used the Kaplan-Meier method to estimate survival and the Cox model was used to assess prognostic factors. All had histology for penile cancer as a basis for diagnosis. For location of the 75% tumor were not specified, followed by 18% located in the glans, 04% in the foreskin. The median survival time was 49 months, 89% presented themselves between stages I and II. Patients with rural occupations had a mean survival time of 75.02 months, patients with non-rural occupations 42.14 months; Patients residing in metropolitan area - Espírito Santo had a mean survival time of 26.03 months, other patients 71.42 months; In patients with compromised lymph nodes, the mean survival time was 30.59 months, and in patients with no compromised lymph nodes, the mean survival time was 75.83 months. This study demonstrates reduced survival in non-rural workers who reside in metropolitan area and who present with compromised lymph nodes and metastasis.

Resumo O objetivo deste artigo é estimar a sobrevida específica dos pacientes com câncer de pênis atendidos em um hospital de referência em oncologia. Analisou-se 100 casos incidentes de pacientes com câncer de pênis que receberam tratamento no hospital, no período de 2000 a 2011, seguimento até 31 de dezembro de 2012. Utilizou-se como fonte de informação o banco de dados do Registro Hospitalar de Câncer e o prontuário do paciente. Utilizou-se o método de Kaplan-Meier para estimar a sobrevida e o modelo de Cox para investigar os fatores prognósticos. Todos possuíam histologia para câncer do pênis como base para o diagnóstico da doença. Para localização do tumor 75% não foram especificados, seguido de 18% na glande, 04% no prepúcio. O tempo mediano de sobrevida foi de 49 meses, 89% apresentavam-se entre os estádios I e II. Pacientes com ocupação rural apresentaram sobrevida média de 75,02 meses, ocupação não rural de 42,14 meses. Os procedentes da Grande Vitória - Espírito Santo sobrevida média de 26,03 e demais pacientes de 71,42 meses. Homens com linfonodo positivo possuíram sobrevida média de 30,59 meses e, sem comprometimento, 75,83 meses. A presença de metástase esteve associada a menores taxas de sobrevida. Trabalhadores não rurais, proveniente da Grande Vitória, com presença de linfonodo acometido e metástase apresentaram pior sobrevida.
Descritores: Neoplasias Penianas/terapia
População Rural
População Urbana
-Neoplasias Penianas/patologia
Prognóstico
Modelos de Riscos Proporcionais
Taxa de Sobrevida
Estudos Retrospectivos
Fatores de Risco
Estudos de Coortes
Seguimentos
Estimativa de Kaplan-Meier
Centros de Atenção Terciária
Metástase Linfática
Pessoa de Meia-Idade
Estadiamento de Neoplasias
Ocupações
Limites: Humanos
Masculino
Adulto
Responsável: BR1.1 - BIREME



página 1 de 14 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde